ArticleCancer immunology, immunotherapy : CII2012

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.

Carmen D Schweighofer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.